Anti-Human EGFR Reference Antibody (Imgatuzumab, RUO) (HF004116)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HF004116
Description	Imgatuzumab (HF004116) is a research-grade recombinant antibody targeting HER1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Humanized
Isotype	IgG1-kappa
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P00533
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	GA201, RG7160, RO5083945, 959963-46-3
Background	Epidermal growth factor receptor (EGFR/ERBB1) is a ~134 kDa protein. Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. EGFR is the therapeutic target of cetuximab (Erbitux) and panitumumab (Vectibix). 1. Arcaro, A. et al. (2000) Molecular and cellular biology 20, 3817-30. PMID: 10805725 2. Runkle, KB. et al. (2016) Molecular cell 62, 385-396. PMID: 27153536 3. Chen, WS. et al. (1989) Cell 59, 33-43. PMID: 2790960 4. Bu, J. et al. (2022) Acta biochimica et biophysica Sinica 54, 400-408. PMID: 35538033 5. Garrett, TP. et al. (2002) Cell 110, 763-73. PMID: 12297049 6. Kochupurakkal, BS. et al. (2005) The Journal of biological chemistry 280, 8503-12. PMID: 15611079 7. Kim, J. et al. (2007) Cancer research 67, 9229-37. PMID: 17909029 8. Lu, C. et al. (2010) Molecular and cellular biology 30, 5432-43. PMID: 20837704
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Imgatuzumab.

References

Datasheet

Anti-Human EGFR Reference Antibody (Imgatuzumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human EGFR Reference Antibody (Imgatuzumab, RUO) (HF004116)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us